Erste Group Bank Lifts Earnings Estimates for Novartis

Novartis AG (NYSE:NVS) – Research analysts at Erste Group Bank boosted their FY2027 earnings per share estimates for shares of Novartis in a report released on Tuesday, May 5th. Erste Group Bank analyst H. Engel now expects that the company will earn $9.77 per share for the year, up from their previous forecast of $9.74. The consensus estimate for Novartis’ current full-year earnings is $8.89 per share.

Novartis (NYSE:NVS) last issued its earnings results on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). Novartis had a return on equity of 38.82% and a net margin of 24.87%.The business had revenue of $13.52 billion during the quarter, compared to the consensus estimate of $13.44 billion. During the same quarter in the previous year, the firm posted $2.28 earnings per share. The company’s revenue for the quarter was down .9% compared to the same quarter last year.

A number of other research firms also recently issued reports on NVS. Morgan Stanley boosted their target price on shares of Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a research report on Thursday, March 26th. Argus raised shares of Novartis from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a research note on Wednesday, March 11th. Wall Street Zen lowered shares of Novartis from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. DZ Bank cut shares of Novartis from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Finally, Citigroup restated a “buy” rating on shares of Novartis in a research note on Thursday, February 5th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Novartis currently has an average rating of “Hold” and a consensus price target of $141.20.

Novartis Price Performance

Novartis stock opened at $145.44 on Friday. The stock has a market capitalization of $277.53 billion, a price-to-earnings ratio of 20.84, a PEG ratio of 2.59 and a beta of 0.46. Novartis has a 52-week low of $104.93 and a 52-week high of $170.46. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.65 and a current ratio of 0.85. The stock’s 50 day moving average price is $153.19 and its two-hundred day moving average price is $144.31.

Institutional Trading of Novartis

Hedge funds and other institutional investors have recently bought and sold shares of the business. J.W. Cole Advisors Inc. raised its holdings in Novartis by 0.6% during the fourth quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock worth $1,348,000 after buying an additional 64 shares during the last quarter. Roundview Capital LLC grew its holdings in shares of Novartis by 2.5% during the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock valued at $374,000 after buying an additional 66 shares during the last quarter. IMA Advisory Services Inc. increased its position in shares of Novartis by 10.9% during the fourth quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after acquiring an additional 70 shares in the last quarter. Abundance Wealth Counselors raised its holdings in shares of Novartis by 0.4% in the 4th quarter. Abundance Wealth Counselors now owns 16,927 shares of the company’s stock worth $2,334,000 after acquiring an additional 73 shares during the last quarter. Finally, Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Novartis by 3.5% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 2,230 shares of the company’s stock worth $307,000 after acquiring an additional 75 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.